2025-03-26

VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD

2025-03-25

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED CHANGE IN USE OF PROCEEDS

2025-03-14

INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY

2025-03-13

DATE OF BOARD MEETING

2025-03-06

VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) COMBINED WITH IMM2510 (PALVERAFUSP) AND WITH OR WITHOUT CHEMOTHERAPY FOR ADVANCED MALIGNANT TUMORS

2025-03-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2025

2025-02-21

COMPLETION OF DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY

2025-02-17

(REVISED) SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY

2025-02-06

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2025

2025-01-24

ARTICLES OF ASSOCIATION

2025-01-24

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

2025-01-13

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NSCLC

2025-01-10

SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY

2025-01-09

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

2025-01-07

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2024

2024-12-30

DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY

2024-12-17

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF NMOSD

2024-12-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2024

2024-12-02

VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE NMPA FOR A PHASE II CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF LUPUS NEPHRITIS

2024-11-28

Next Day Disclosure Return